Pipeline
Overview
Our drug candidates, ‘1104 and ‘1805, are in development to shift the immune system from a pro-inflammatory state to a regulated homeostatic state. They aim to restore immune homeostasis with a patient convenient administration and without suppressing the immune system so that it can function naturally as a protective host defense mechanism. They have both demonstrated efficacy signals and positive safety in many preclinical and clinical studies to date, with potential to offer a significant improvement over current therapy.
Our Pipeline
‘1104
Th2 and Treg/Breg (Selectively targets allergic APCs)
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Notes
Eosinophilic Esophagitis
Phase 2 complete; Phase 2b planned (bridge study: IV and SC)
Atopic Dermatitis
Animal model data set and upcoming Phase 2
Allergen Sensitivity
Will inform Atopic Dermatitis trial
Allergen sensitivity completed
Other Eosinophilic Gastrointestinal
Phase 2 planning following EoE Ph2b completion
Asthma
Multiple animal model data sets; Phase 2 design underway
Food Allergy
Animal model data
‘1805
APC Modifier Treg
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Notes
Rheumatoid Arthritis
Phase 2b ready
Ulcerative Colitis
Ex-vivo data
Crohn’s
Ex-vivo data
‘1104 has been shown to be safe and well tolerated in five clinical studies. In a Phase 2a study of eosinophilic esophagitis (EoE), ‘1104 met its primary endpoint, reducing key inflammatory cells, and lead to improved patient symptoms. ‘1104 has also shown a rapid clinical signal in a Phase 2a allergic disease mapping study. We are preparing for a larger Phase 2 study in EoE based on these positive outcomes, exploring patient-friendly routes of administration such as subcutaneous and sublingual. We also plan to investigate ‘1104 in other allergic conditions with large unmet need, including atopic dermatitis (AD).
‘1805 has demonstrated a trend to remission of disease, which correlates with a reduction in the associated inflammatory biomarkers in rheumatoid arthritis in a Phase 2a study.